Small Intestinal Bacterial Overgrowth (SIBO)
Small intestinal bacterial overgrowth (SIBO) refers to an abnormal amount of bacteria in the small intestine. The exact causes are unknown, and diagnosis can be challenging because SIBO shares symptoms with several other diseases. SIBO can be treated with antibiotics, and certain probiotics may enhance their efficacy.
Small intestinal bacterial overgrowth (SIBO) is a form of dysbiosis (or abnormal gut microbiota) characterized by an excessive amount of bacteria in the small intestine, sometimes due to elevations in bacteria that are usually found only in the large intestine. It is considered both a clinical syndrome and a potential mechanism that could contribute to the progression of other diseases.
Normally, the environment of the small intestine — including the acidity, oxygen level, motility (the ability of muscles to contract), and immune cells — control microbial growth. If this environment is modified by acid-suppressing medications, surgery, or disease, microbes can rapidly divide and take up residence in previously inhospitable areas of the small intestine, resulting in SIBO.
SIBO often occurs with other GI diseases that have overlapping symptoms, which can complicate diagnosing either accurately.
SIBO can be diagnosed with breath tests or a duodenal aspirate culture (a lab test done on a small fluid sample from the small intestine), but the lack of standardization makes accurate diagnosis challenging. Breath tests are an indirect way to measure bacteria in the small intestine, but their ease and low invasiveness make them a more common diagnostic tool than the fluid test.
Clinicians have yet to reach a consensus on diagnostic criteria for a positive result of either test, but it’s generally accepted that SIBO is present when there is a concentration of 103 to 105 colony forming units per milliliter (CFU/mL) in a fluid sample. 
SIBO is conventionally treated with certain classes of antibiotics that are poorly absorbed — unlike systemic antibiotics, which easily enter circulation — so they act primarily in the intestines. This leads to fewer side effects and lower chances of antimicrobial resistance, which leads to potentially deadly microbes becoming unaffected by antibiotics. SIBO is generally considered to be cured (often referred to as being eradicated or decontaminated) based on normal breath test results.
Fecal microbiota transplants (FMT) aren’t an established treatment yet, but there is promising preliminary research. 
Probiotics may be useful for treating SIBO, but it’s not clear which strains (or combinations of strains) are optimal. Some research has also shown good results from probiotics used alongside during or immediately after antibiotic treatment.
Other treatments, such as prebiotics, curcumin, ursodeoxycholic acid, daikenchuto (a traditional Japanese herbal preparation), Serum-derived bovine immunoglobulin/protein isolate, and some antimicrobial herbs have also been studied, but there isn’t enough evidence to recommend their use.
Very little research has been done on dietary interventions for SIBO specifically, so most recommendations are based on weak or anecdotal evidence. Some dietary patterns, such as the low-fodmap, low-sugar or specific carbohydrate, or elemental diets may reduce some of the symptoms associated with SIBO, but their effects on the condition itself are unknown. 
Although SIBO hasn’t been identified as a definitive cause or consequence of any other disease, it is associated with a number of conditions that create an abnormal intestinal environment, which could include:
- A less acidic (more hospitable) small intestine
- Slower (more accessible) transit of food through the GI tract
- Abnormal muscular contractions that push contents (and microbes) backward, from the large to the small intestine
- Reduced immune activity that would normally regulate microbial growth
- ^Y A Kucheryavyy, D N Andreev, I V MaevPrevalence of small bowel bacterial overgrowth in patients with functional dyspepsia: a meta-analysisTer Arkh.(2020 Dec 15)
- ^Ayesha Shah, Mark Morrison, Daniel Burger, Neal Martin, Justin Rich, Mike Jones, Natasha Koloski, Marjorie M Walker, Nicholas J Talley, Gerald J HoltmannSystematic review with meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel diseaseAliment Pharmacol Ther.(2019 Mar)
- ^Arjun Gandhi, Ayesha Shah, Michael P Jones, Natasha Koloski, Nicholas J Talley, Mark Morrison, Gerald HoltmannMethane positive small intestinal bacterial overgrowth in inflammatory bowel disease and irritable bowel syndrome: A systematic review and meta-analysisGut Microbes.(Jan-Dec 2021)
- ^George B Saffouri, Robin R Shields-Cutler, Jun Chen, Yi Yang, Heather R Lekatz, Vanessa L Hale, Janice M Cho, Eric J Battaglioli, Yogesh Bhattarai, Kevin J Thompson, Krishna K Kalari, Gaurav Behera, Jonathan C Berry, Stephanie A Peters, Robin Patel, Audrey N Schuetz, Jeremiah J Faith, Michael Camilleri, Justin L Sonnenburg, Gianrico Farrugia, Jonathan R Swann, Madhusudan Grover, Dan Knights, Purna C KashyapSmall intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disordersNat Commun.(2019 May 1)
- ^Ali Rezaie, Michelle Buresi, Anthony Lembo, Henry Lin, Richard McCallum, Satish Rao, Max Schmulson, Miguel Valdovinos, Salam Zakko, Mark PimentelHydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American ConsensusAm J Gastroenterol.(2017 May)
- ^Giuseppe Losurdo, Gioacchino Leandro, Enzo Ierardi, Francesco Perri, Michele Barone, Mariabeatrice Principi, Alfredo Di LeoBreath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: A Systematic Review With Meta-analysisJ Neurogastroenterol Motil.(2020 Jan 30)
- ^L Gatta, C ScarpignatoSystematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowthAliment Pharmacol Ther.(2017 Mar)
- ^Changqing Zhong, Changmin Qu, Baoyan Wang, Shuwen Liang, Bolun ZengProbiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current EvidenceJ Clin Gastroenterol.(2017 Apr)
- ^Fenghua Xu, Ning Li, Chun Wang, Hanyang Xing, Dongfeng Chen, Yanling WeiClinical efficacy of fecal microbiota transplantation for patients with small intestinal bacterial overgrowth: a randomized, placebo-controlled clinic studyBMC Gastroenterol.(2021 Feb 6)
- ^Konstantinos Leventogiannis, Paraskevas Gkolfakis, Georgios Spithakis, Aikaterini Tsatali, Aikaterini Pistiki, Athanasios Sioulas, Evangelos J Giamarellos-Bourboulis, Konstantinos TriantafyllouEffect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial OvergrowthProbiotics Antimicrob Proteins.(2019 Jun)
- ^Grettel García-Collinot, Eduardo Osiris Madrigal-Santillán, Michel A Martínez-Bencomo, Rosa A Carranza-Muleiro, Luis J Jara, Olga Vera-Lastra, Daniel H Montes-Cortes, Gabriela Medina, María Pilar Cruz-DomínguezEffectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic SclerosisDig Dis Sci.(2020 Apr)
- ^Mark Pimentel, Tess Constantino, Yuthana Kong, Meera Bajwa, Abolghasem Rezaei, Sandy ParkA 14-day elemental diet is highly effective in normalizing the lactulose breath testDig Dis Sci.(2004 Jan)
- ^Emma Altobelli, Valerio Del Negro, Paolo Matteo Angeletti, Giovanni LatellaLow-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-AnalysisNutrients.(2017 Aug 26)
- ^J S Barrett, R B Gearry, J G Muir, P M Irving, R Rose, O Rosella, M L Haines, S J Shepherd, P R GibsonDietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colonAliment Pharmacol Ther.(2010 Apr)
- ^Clara Nilholm, Ewa Larsson, Emily Sonestedt, Bodil Roth, Bodil OhlssonAssessment of a 4-Week Starch- and Sucrose-Reduced Diet and Its Effects on Gastrointestinal Symptoms and Inflammatory Parameters among Patients with Irritable Bowel SyndromeNutrients.(2021 Jan 28)
- ^Xin Feng, Xiao-Qing Li, Zheng JiangPrevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysisClin Rheumatol.(2021 Aug)
- ^Uday C Ghoshal, Deepakshi Srivastava, Asha Misra, Ujjala GhoshalA proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trialEur J Gastroenterol Hepatol.(2016 Mar)
- ^Karn Wijarnpreecha, Susan Lou, Kanramon Watthanasuntorn, Paul T Kroner, Wisit Cheungpasitporn, Frank J Lukens, Surakit Pungpapong, Andrew P Keaveny, Patompong UngprasertSmall intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysisEur J Gastroenterol Hepatol.(2020 May)
- ^Roman Maslennikov, Chavdar Pavlov, Vladimir IvashkinSmall intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysisHepatol Int.(2018 Nov)
- ^Ayesha Shah, Erin Shanahan, Graeme A Macdonald, Linda Fletcher, Pegah Ghasemi, Mark Morrison, Mike Jones, Gerald HoltmannSystematic Review and Meta-Analysis: Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Liver DiseaseSemin Liver Dis.(2017 Nov)
- ^Chloé Melchior, Guillaume Gourcerol, Valérie Bridoux, Philippe Ducrotté, Jean-François Quinton, Anne-Marie LeroiEfficacy of antibiotherapy for treating flatus incontinence associated with small intestinal bacterial overgrowth: A pilot randomized trialPLoS One.(2017 Aug 1)
- ^Saravana Ruban Gurusamy, Ayesha Shah, Nicholas J Talley, Natasha Koloski, Michael P Jones, Marjorie M Walker, Mark Morrison, Gerald HoltmannSmall Intestinal Bacterial Overgrowth in Functional Dyspepsia: A Systematic Review and Meta-AnalysisAm J Gastroenterol.(2021 May 1)
- ^Binrui Chen, John Jae-Woo Kim, Yawen Zhang, Lijun Du, Ning DaiPrevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysisJ Gastroenterol.(2018 Jul)
- ^Jean-Marc Sabate, Muriel Coupaye, Séverine Ledoux, Benjamin Castel, Simon Msika, Benoit Coffin, Pauline JouetConsequences of Small Intestinal Bacterial Overgrowth in Obese Patients Before and After Bariatric SurgeryObes Surg.(2017 Mar)
- ^Bara El Kurdi, Sumbal Babar, Mahmoud El Iskandarani, Adam Bataineh, Markus M Lerch, Mark Young, Vijay P SinghFactors That Affect Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Pancreatitis: A Systematic Review, Meta-Analysis, and Meta-RegressionClin Transl Gastroenterol.(2019 Sep)
- ^C Jacobs, E Coss Adame, A Attaluri, J Valestin, S S C RaoDysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowthAliment Pharmacol Ther.(2013 Jun)
- ^Tingting Su, Sanchuan Lai, Allen Lee, Xingkang He, Shujie ChenMeta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowthJ Gastroenterol.(2018 Jan)
- ^Mohammad-Ayman A Safi, Asif A Jiman-Fatani, Omar I SaadahSmall intestinal bacterial overgrowth among patients with celiac disease unresponsive to a gluten free dietTurk J Gastroenterol.(2020 Nov)
- ^Wolfgang Knitsch, Jean-Louis Vincent, Stefan Utzolino, Bruno François, Tamás Dinya, George Dimopoulos, İlhan Özgüneş, Juan Carlos Valía, Philippe Eggimann, Cristóbal León, Philippe Montravers, Stephen Phillips, Lorraine Tweddle, Andreas Karas, Malcolm Brown, Oliver A CornelyA randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infectionsClin Infect Dis.(2015 Dec 1)
- ^Hua-Jian Hu, Guo-Qiang Zhang, Qiao Zhang, Shristi Shakya, Zhong-Yue LiProbiotics Prevent Candida Colonization and Invasive Fungal Sepsis in Preterm Neonates: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsPediatr Neonatol.(2017 Apr)
- ^Gaichao Hong, Ying Li, Min Yang, Gangping Li, Wei Qian, Hanhua Xiong, Tao Bai, Jun Song, Lei Zhang, Xiaohua HouGut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome: An explorative studyNeurogastroenterol Motil.(2020 Nov)